Volatus Aerospace Opens 53,000-Square-Foot Mirabel Facility, Establishing Domestic Manufacturing Base for Autonomous Defence Systems
Volatus Aerospace Closes $34.5M Bought Deal Public Offering
Volatus Aerospace Partners with UCan Brave Tech to Advance Sovereign Canada–Ukraine Defence Technologies
Volatus Aerospace Inc. Announces $30 Million Bought Deal Public Offering of Common Shares
Volatus Aerospace Introduces Canadian Sovereign AI Flight Controller and Autonomy Stack at CANSEC 2026
Volatus Aerospace Selected to Advance to Next Phase of U.S. Drone Dominance Program
Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
Fleetcor Technologies Q1 Earnings Call Highlights
Volatus Aerospace Inc. (FLT:CA) Q1 2026 Earnings Call Transcript
Volatus Aerospace Reports First Quarter 2026 Financial Results, Records Highest Q1 Gross Margins in Company's History
Volatus Aerospace to Release First Quarter 2026 Financial Results and Host Earnings Call on May 14, 2026
Fleetcor Technologies Q4 Earnings Call Highlights
Volatus Aerospace Inc. (FLT:CA) Q4 2025 Earnings Call Transcript
Volatus Aerospace Inc. (FLT) Opens the Market
Volatus Aerospace Announces Graduation to Toronto Stock Exchange; Trading to Commence March 20, 2026
Volatus Aerospace Executes Contract to Develop and Commercialize Heavy-Lift Offshore Cargo Drone Deliveries for Wind Turbine Operations
Volatus Aerospace Receives Conditional Approval to Graduate to the Toronto Stock Exchange
Volatus Aerospace Inc. (FLT:CA) Discusses Impact of Canada's Defense Industrial Strategy on Drone and Autonomous Systems Market Transcript
Volatus Aerospace Appoints CTO to Accelerate Sovereign Autonomy and Defence Capabilities
Volatus Aerospace Inc. Named in 2026 TSX Venture 50 List of Top Performing Companies
Volatus Aerospace Awarded $9M Defence Contract from NATO Partner, Accelerating Growth in Uncrewed Systems
Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
Volatus Aerospace Inc. (FLT:CA) Q3 2025 Earnings Call Transcript
Volatus Aerospace Releases Record Third Quarter Financial Results
Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting
Volatus Aerospace Inc. Announces Restatement of Q2 2025 Financial Results
Volatus Aerospace to Attend the 2025 Maxim Growth Summit
Volatus Aerospace and VoltaXplore Sign LOI for Canadian-Made Battery Supply to Power Next-Gen Drones
Volatus Aerospace and VoltaXplore Sign LOI for Canadian-Made Battery Supply to Power Next-Gen Drones
Volatus Aerospace Secures Major Multi-Year Agreement with a Leading North American Power Utility to Provide Drone-Based Services
Volatus Aerospace Releases Q2 2025 Financial Results
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
Volatus Aerospace Inc. Announces Closing of Quebec Led Institutional “Bought Deal” Private Placement
Volatus Aerospace Inc. Announces “Bought Deal” Private Placement
Volatus Aerospace Launches Condor XL Heavy-Lift Drone Program
Volatus Aerospace Awarded $560,000 International Training Contract with NATO Member Country
Volatus Aerospace Supports Canada's Commitment to Strengthening Defense and NATO Alignment
Volatus Aerospace Inc. Secures $3 Million in Financing from Existing Major Institutional Investor and Provides Corporate Update
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia
Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025
Volatus Releases Q1 2025 Financial Results
Volatus Aerospace Inc. Announces Shares-for-Debt Transaction
Volatus Aerospace Inc. Completes Shares-for-Debt Settlement of Unsecured Convertible Debentures
Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202
Volatus Releases Fourth Quarter and Fiscal Year 2024 Financial Results
Volatus Announces $2,000,000 Financing
Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting
Senti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML
Volatus Aerospace Gains Clearance for High-Value RPAS Deployment in Oil & Gas Sector
Volatus Aerospace Inc. Announces Shares-for-Debt Settlement of Unsecured Convertible Debentures to Strengthen Balance Sheet